Catherine Fenselau has conducted research in mass spectrometry and its applications in pharmacology for twenty-five years. Her current research program addresses the mechanisms by which cancer cells become resistant to anti-cancer drugs during treatment. Her group also works to make mass spectrometry a fieldable method for rapid identification of microorganisms. She is associate editor of Analytical Chemistry, a founding council member of the International Human Proteome Organization, founding President of U.S. HUPO, past president of the American Society for Mass Spectrometry, and founding editor of Biomedical Mass Spectrometry (now Journal of Mass Spectrometry). Fenselau received the A.B. from Bryn Mawr College in and a Ph.D. from Stanford University.